# CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

> **NCT03233854** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Stanford University** · enrollment: 56 (actual)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- CD19 Positive
- Minimal Residual Disease
- Philadelphia Chromosome Positive

## Interventions

- **BIOLOGICAL:** Chimeric Antigen Receptor T-Cell Therapy
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Questionnaire Administration
- **DRUG:** NKTR-255

## Key facts

- **NCT ID:** NCT03233854
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-01
- **Primary completion:** 2023-06-20
- **Final completion:** 2035-09-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03233854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03233854, "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03233854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*